EUCTR2012-000327-40-BE进行中（未招募）1 期
A Double-blind, Randomized, Placebo-controlled, Multicenter, DoseEscalation Study to Select and Evaluate an Oral Modified Release Formulation of Omecamtiv Mecarbil in Subjects with Heart Failure and Left Ventricular Systolic Dysfunction
Amgen Inc.0 个研究点目标入组 570 人开始时间: 2013年6月14日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 570
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Dose Escalation Cohorts:
- •4.1.1 Subject has provided informed consent.
- •4.1.2 Male or female = 18 years and = 85 years of age at the time of informed consent.
- •4.1.3 History of chronic HF, defined as requiring treatment for HF for a minimum of 4 weeks prior to screening.
- •4.1.4 Treated for HF with stable, optimal pharmacological therapy. In general, optimal treatment will include a beta-blocker and an ACE inhibitor and/or an angiotensin receptor blocker at doses shown to be efficacious in HF trials, unless not tolerated. Stable medical therapy is defined as having no new HF drug class introduced or uptitrated = 4 weeks prior to randomization.
- •4.1.5 LVEF = 40% (echocardiogram, radionuclide ventriculography,
- •cardiac magnetic resonance imaging, or contrast ventriculography) within 18 months prior to randomization and without an intervening value of > 40%.
- •4.1.6 NT-proBNP = 200 pg/mL (= 1200 pg/mL if the subject has atrial fibrillation at presentation) at screening; (Note: enrollment of subjects with atrial fibrillation will be limited to up to approximately 20% of planned enrollment in each cohort).
- •Expansion Phase:
- •4.1.7 Subject has provided informed consent.
- •4.1.8 Male or female = 18 years and = 85 years of age at the time of informed consent.
- •4.1.9 History of chronic HF, defined as requiring treatment for HF for a minimum of 4 weeks prior to screening.
- •4.1.10 Treated for HF with stable, optimal pharmacological therapy. In general, optimal treatment will include a beta-blocker and an ACE inhibitor and/or an angiotensin receptor blocker at doses shown to be efficacious in HF trials, unless not tolerated. Stable medical therapy is defined as having no new HF drug class introduced or uptitrated = 4 weeks prior to randomization.
- •4.1.11 NYHA class II or III symptoms.
- •4.1.12 LVEF = 40% by centrally read screening echocardiogram.
- •4.1.13 Acceptable echocardiographic image quality of screening
- •echocardiogram per central echo core laboratory
- •4.1.14 NT-proBNP = 200 pg/mL (= 23.60 pmol/L) [= 1200 pg/mL (= 141.60 pmol/L) if the subject has atrial fibrillation at presentation] at screening; (Note: enrollment of subjects with atrial fibrillation will be limited to up to approximately 20% of planned cohort enrollment).
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 280
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 290
排除标准
- •Dose Escalation Cohorts and Expansion Phase:
- •4.2.1 Cardiac resynchronization therapy (CRT) or ICD implantation within 30 days prior to enrollment.
- •4.2.2 NYHA class IV.
- •4.2.3 Hospitalization for any reason within 30 days prior to randomization.
- •4.2.4 Likely to receive within 3 months after randomization, in the opinion of the Investigator, planned revascularization, implantation of ICD or CRT, ventricular assist device, continuous or intermittent inotropic therapy, hospice care, or cardiac transplant.
- •4.2.5 Severe uncorrected valvular heart disease.
- •4.2.6 Hypertrophic obstructive cardiomyopathy, active myocarditis, or constrictive pericarditis, or clinically significant congenital heart disease.
- •4.2.7 Acute myocardial infarction, unstable angina or persistent angina at rest within 30 days prior to randomization .
- •4.2.8 Chronic antiarrhythmic therapy, with the exception of amiodarone.
- •4.2.9 Routinely scheduled outpatient IV infusions for HF (eg, inotropes, vasodilators [eg, nesiritide], diuretics) or routinely scheduled ultrafiltration.
- •4.2.10 Systolic BP > 160 mm Hg or < 90 mm Hg, or diastolic BP > 90 mm Hg, or HR > 110 beats per minute (bpm) or HR < 50 bpm at screening.
- •4.2.11 Estimated glomerular filtration rate (eGFR) < 30 mL/min/1.73m2 at screening.
- •4.2.12 Currently taking, or has taken within 14 days prior to randomization, a potent CYP3A4 inhibitor.
- •4.2.13 Currently taking, or has taken within 28 days prior to randomization, a potent CYP3A4 inducer.
- •4.2.14 Severe, concomitant noncardiovascular disease that is expected to reduce life expectancy to less than 1 year.
- •4.2.15 Recipient of any major organ transplant (eg, lung, liver, heart, bone marrow, renal) or receiving renal replacement therapy by dialysis.
- •4.2.16 Malignancy within 5 years prior to randomization with the following exceptions: localized basal or squamous cell carcinoma of the skin or cervical intraepithelial neoplasia.
- •4.2.17 Known untreated hypothyroidism or hyperthyroidism, adrenal insufficiency, active vasculitis due to collagen vascular disease.
- •4.2.18 Hepatic impairment
- •4.2.19 Any acute or serious co-morbid condition (eg, major infection or hematologic, renal, metabolic, gastrointestinal or endocrine dysfunction) that, in the judgment of the investigator, could lead to premature termination of study participation or interfere with the measurement of, or the interpretation of, the efficacy and safety assessments in the study
- •4.2.20 Previously received omecamtiv mecarbil.
- •4.2.21 Currently receiving treatment in another investigational device or drug study, or less than 30 days since ending treatment on another investigational device or drug study.
- •4.2.22 Recent (within 3 months) history of alcohol or illicit drug abuse based on self-report.
- •4.2.23 Known sensitivity to any of the products to be administered during dosing.
- •4.2.24 Female subject of childbearing potential who is not willing to inform her partner of her participation in this clinical study and to use two acceptable methods of effective birth control or abstinence or surgical contraceptive methods (vasectomy or bilateral tubal ligation) during treatment with IP (omecamtiv mecarbil or placebo) and for an additional 5 days after the last dose of IP. Male subject with a female partner of childbearing potential and not willing to inform his partner of his participation in this clinical study
- •- A female is considered of childbearing potential unless she has had a hysterectomy, bilate
研究者
相似试验
进行中（未招募）
1 期
Study to assess the tolerability and efficacy of AMG 145 in patients withheterozygous familial hypercholesterolemiaHeterozygous Familial HypercholesterolemiaMedDRA version: 14.1Level: LLTClassification code 10057079Term: Heterozygous familial hypercholesterolemiaSystem Organ Class: 100000004850EUCTR2012-001365-32-NLAmgen Inc331
进行中（未招募）
1 期
Effect of Evolocumab in Patients at High Cardiovascular Risk Without Prior Myocardial Infarction or StrokeMedDRA version: 21.0Level: LLTClassification code 10058110Term: DyslipidemiaSystem Organ Class: 10027433 - Metabolism and nutrition disordersDyslipidemiaEUCTR2018-004565-14-PLAmgen Inc.12,000
进行中（未招募）
不适用
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure TrialHeart Failure Subjects with Symptomatic Left Ventricular Systolic Dysfunction and AnemiaMedDRA version: 14.0Level: PTClassification code 10007559Term: Cardiac failure congestiveSystem Organ Class: 10007541 - Cardiac disordersEUCTR2005-005278-59-LTAmgen Inc.2,600
进行中（未招募）
1 期
A Study Assessing the Impact of Additional LDL-Cholesterol Reduction on Major Cardiovascular Events when Evolocumab (AMG 145) is used in combination With Statin Therapy In Patients with Clinically Evident Cardiovascular DiseaseDyslipidemiaMedDRA version: 19.0Level: LLTClassification code 10020604Term: HypercholesterolemiaSystem Organ Class: 100000004861MedDRA version: 19.0Level: LLTClassification code 10058110Term: DyslipidemiaSystem Organ Class: 100000004861EUCTR2012-001398-97-LTAmgen Inc27,500
进行中（未招募）
不适用
Study to Evaluate the Safety and Efficacy of IV Infusion Treatment With Omecamtiv Mecarbil in Subjects With Left Ventricular Systolic Dysfunction Hospitalized for Acute Heart FailureAcute heart failureMedDRA version: 14.1Level: LLTClassification code 10000803Term: Acute heart failureSystem Organ Class: 10007541 - Cardiac disordersEUCTR2010-021003-24-LTAmgen Inc600